Clinical Trial Finder

« Return to Results

View on ClinicalTrials.gov Export CSV

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Program Status

Active, not recruiting

Phase

Phase 1

Prior Immunotherapy Allowed

Yes

CRC-directed Trial

Drugs

CC-95251, cetuximab, Rituximab

Tags

MSS/ MMRp

Comments

CC-95251: monoclonal antibody, SIRPα antagonist.
cetuximab: EGFR inhibitor (Erbitux).
Therapies that block the CD47/SIRPα axis stimulate phagocytosis of cancer cells in vitro and anti-tumour immune responses in vivo. Phagocytosis in response to CD47/SIRPα-blocking agents results in antigen uptake and presentation, thereby linking the innate and adaptive immune systems.

Location	Location Status
United States
Local Institution - 105 Birmingham, Alabama 35294	Active, not recruiting
Local Institution - 101 Scottsdale, Arizona 85258	Active, not recruiting
Local Institution - 112 Sacramento, California 95817	Active, not recruiting
Rocky Mountain Cancer Centers, LLP [Aurora-COAU] Aurora, Colorado 80012	Active, not recruiting
Local Institution - 115 Saint Louis, Missouri 63110	Active, not recruiting
Local Institution - 110 New York, New York 10016	Active, not recruiting
Local Institution - 109 Charlotte, North Carolina 28204	Active, not recruiting
Local Institution - 106 Oklahoma City, Oklahoma 73104	Active, not recruiting
Local Institution - 113 Portland, Oregon 97213	Active, not recruiting
Local Institution - 107 Pittsburgh, Pennsylvania 15232	Active, not recruiting
Local Institution - 102 Nashville, Tennessee 37203-1625	Active, not recruiting
Local Institution - 108 Houston, Texas 77030	Active, not recruiting
Local Institution - 103 San Antonio, Texas 78229	Active, not recruiting
Australia
Local Institution - 301 Heidelberg, Victoria 3084	Active, not recruiting
Local Institution - 303 Melbourne, Victoria 3000	Active, not recruiting
Canada
Local Institution - 201 Edmonton, Alberta T6G 1Z2	Active, not recruiting
Local Institution - 202 Toronto, Ontario M5G 2M9	Active, not recruiting
France
Local Institution - 402 Borddeaux Cedex 33076	Active, not recruiting
Local Institution - 406 Creteil 94010	Active, not recruiting
Local Institution - 405 Marseille 13009	Active, not recruiting
Local Institution - 404 Nantes Cedex 01 44093	Active, not recruiting
Local Institution - 403 Rouen 76038	Active, not recruiting
Local Institution - 401 Villejuif CEDEX 94805	Active, not recruiting
Italy
Local Institution - 701 Bologna 40138	Active, not recruiting
Local Institution - 702 Napoli, Campania 80131	Active, not recruiting
Korea, Republic of
Local Institution - 604 Seoul 03722	Active, not recruiting
Local Institution - 603 Seoul 06351	Active, not recruiting
Local Institution - 602 Seoul 3080	Active, not recruiting
Local Institution - 601 Seoul 5505	Active, not recruiting
Spain
Local Institution - 504 Madrid 28040	Active, not recruiting
Local Institution - 502 Malaga 29010	Active, not recruiting
Local Institution - 501 Salamanca 37007	Active, not recruiting
United Kingdom
Local Institution - 802 Manchester M20 4BX	Active, not recruiting

Inclusion Criteria

Inclusion Criteria:

Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma
Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1
Eastern cooperative oncology group performance status of 0 or 1

Exclusion Criteria

Exclusion Criteria:

High-grade lymphomas (Burkitt's or lymphoblastic)
Has cancer with symptomatic central nervous system (CNS) involvement
History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months

Other protocol-defined inclusion/exclusion criteria apply

NCT ID

NCT03783403

Date Trial Added

2018-12-21

Updated Date

2023-12-01